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Non-sense mutations on both alleles of either the type
VII collagen gene (COL7A1) or the genes encoding
laminin 5 (LAMA3, LAMB3, or LAMC2) usually result
in clinically severe forms of recessive dystrophic or
junctional epidermolysis bullosa, respectively. In this
study we assessed two unrelated families whose
mutations in genomic DNA predicted severe recess-
ive dystrophic epidermolysis bullosa or junctional
epidermolysis bullosa phenotypes but in whom the
manifestations were milder than expected. The recess-
ive dystrophic epidermolysis bullosa patients had a
homozygous single base-pair frameshift mutation in
exon 19 of COL7A1 (2470insG). Clinically, there was
generalized blistering but only mild scarring. Skin
biopsy revealed positive type VII collagen immuno-
reactivity and recognizable anchoring fibrils. The junc-
tional epidermolysis bullosa patients were compound
heterozygotes for a frameshift/non-sense combination
of mutations in exons 3 and 17 of LAMB3 (29insC/
Q834X). These patients did not have the lethal form
of junctional epidermolysis bullosa but, as adults,
displayed the milder generalized atrophic benign
epidermolysis bullosa variant. There was undetectable
laminin 5 staining at the dermal–epidermal junction
using an antibody to the b3 chain, but faintly positive
In recent years the molecular basis for the main subtypesof epidermolysis bullosa (EB) has been elucidated withpathogenetic mutations delineated in 10 different genesencoding structural components of the dermal–epidermaljunction (Uitto et al, 1997). Within the particular forms of
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a3 and g2 chain labeling, and there was variable
hypoplasia of hemidesmosomes. To explain the milder
recessive dystrophic epidermolysis bullosa and junc-
tional epidermolysis bullosa phenotypes in these
families, reverse transcription–polymerase chain
reaction, using RNA extracted from frozen skin, was
able to provide evidence for some rescue of mutant
mRNA transcripts with restoration of the open- read-
ing frame. In the recessive dystrophic epidermolysis
bullosa patients, transcripts containing in-frame
skipping of exon 19 of COL7A1 in the cDNA were
detected, and in the junctional epidermolysis bullosa
patients transcripts with in-frame skipping of exon 17
of LAMB3 were identified. The truncated proteins
encoded by these transcripts are expected to lack
certain critical domains involved in cell-matrix
attachment, but may still be able to contribute to
adhesion thereby moderating the severity of the
skin blistering. This study shows the limitations in
predicting phenotype in epidermolysis bullosa solely
based on mutation analysis of genomic DNA and
emphasizes the importance of immunohistochemistry,
electron microscopy, and mRNA assessment as parallel
investigations. Key words: blister/genodermatosis/laminin
5/type VII collagen. J Invest Dermatol 113:314–321, 1999
EB some genotype–phenotype correlations have also become
apparent. For example, severe, mutilating (Hallopeau–Siemens)
forms of generalized recessive dystrophic EB (RDEB) (MIM
226600) typically result from non-sense or frameshift mutations on
both alleles of the gene encoding type VII collagen (COL7A1),
the main component of anchoring fibrils at the dermal–epidermal
junction (Christiano et al, 1994a; Hovnanian et al, 1994). Such
mutations usually give rise to a complete absence of immunostaining
for type VII collagen in patient skin and a lack of ultrastructurally
recognizable anchoring fibrils beneath the lamina densa (Tidman
and Eady, 1985; Bruckner-Tuderman et al, 1989; McGrath et al,
1993). Similarly, in the severe, lethal (Herlitz) type of junctional
EB (JEB) (MIM 226700), the mutations normally comprise non-
sense or frameshift mutations on both alleles of any of the three
genes encoding the α3, β3, or γ2 polypeptides of laminin 5
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(LAMA3, LAMB3, and LAMC2, respectively) (Uitto et al, 1995,
1997). These types of mutations lead to a complete absence
of laminin 5 immunoreactivity and ultrastructural changes in
hemidesmosomes, which may be hypoplastic or reduced in number
or both (Tidman and Eady, 1986; Verrando et al, 1991).
In severe forms of EB, the consequences of non-sense mutations,
or frameshift mutations leading to downstream premature stop
codons, have been studied at mRNA and protein levels. Although
these mutations may lead to the synthesis of a truncated gene
product, the predominant effect appears to be low steady-state
mRNA levels resulting from non-sense-mediated mRNA decay
and a completely undetectable gene product. Such changes have
been demonstrated in both type VII collagen and laminin 5
(Pulkkinen et al, 1994; Christiano et al, 1997a).
In this report we describe examples of partial recovery of mRNA
transcripts containing non-sense or frameshift mutations through
aberrant splicing of mRNA resulting in in-frame exon skipping in
the cDNA in adult patients in one family with RDEB and a
different family with JEB. Despite the presence of frameshift
mutations on both alleles of COL7A1 in the RDEB family, the
affected individuals showed only mild scarring, there was positive
immunostaining for type VII collagen at the dermal–epidermal
junction, and clearly discernible anchoring fibrils were seen on
transmission electron microscopy. The JEB patients were compound
heterozygotes for a non-sense/frameshift combination of mutations
in LAMB3, but displayed a nonlethal JEB phenotype, had positive
laminin 5 staining of skin sections with α3 and γ2 chain-specific
antibodies, and showed variable changes in the morphology of
hemidesmosomes.
Elucidation of mutations in several patients with different forms
of DEB or JEB has proved useful in defining both disease diagnosis
and prognosis for affected individuals, but this study shows the
importance of immunohistochemistry, electron microscopy, and
mRNA studies in providing a better understanding of disease
pathology in EB and in optimizing genetic counseling for affected
individuals.
MATERIALS AND METHODS
Clinical features of RDEB family Three Hispanic-Mexican sisters
(aged 18, 22, and 24 y) from a consanguineous family presented with a
history of generalized trauma-induced skin blistering since the first week
of life. Full clinicopathologic features have been reported previously
(Salas-Alanis et al, 1998), but of note, in spite of the widespread blistering,
none of the affected individuals had any signs of fusion of the fingers or toes
(pseudosyndactyly) that usually characterizes the generalized, Hallopeau–
Siemens form of RDEB, and none had any substantive flexural disease
involvement that is present in the inversa subtype of the disorder (Fine
et al, 1991).
Clinical features of JEB family Two caucasian German brothers (aged
32 and 39 y) from unrelated parents presented with skin blistering that had
been present since the first 2–3 d of life. Trauma-induced blistering
continued throughout childhood and into adult life and they also developed
additional abnormalities affecting the hair, teeth, and nails, collectively
constituting a specific form of nonlethal JEB termed generalized atrophic
benign EB (Darling et al, 1998). Further clinical details of both individuals
have been documented elsewhere (Swensson and Christophers, 1998).
Polymerase chain reaction (PCR) amplification After informed
consent, genomic DNA was isolated from peripheral blood leukocytes
and used as a template for amplification of COL7A1 and LAMB3 genomic
sequences, as described in detail elsewhere (Pulkkinen et al, 1995; Christiano
et al, 1997b) (GenBank L23982, U17745, U17757). Specifically, to
amplify exon 19 of COL7A1 the following primers were used: sense
primer 59-CCCTAACCATTGCTGTATGC-39, anti-sense primer 59-
CCAAAGGCTCACTACCAATC-39. To amplify exon 3 of LAMB3, the
primers were: sense primer 59-AATTATTACTGCCAGCAGCG-39, anti-
sense primer 59-TACATTTCCTCTTGCCCAAC-39, and the primer sets
for exon 17 of LAMB3 were: sense primer 59 GTGGATTGGTT-
ATTGAGGG-39, anti-sense primer 59-AATGGGAACTCTGACTTGCC.
For PCR amplification, 250 ng of genomic DNA was used as the template
in an amplification buffer containing 6.25 pmol of the primers, 37.5 nmol
MgCl2, 5 mmol of each nucleotide and 1.25 U Taq polymerase (Perkin-
Elmer, Warrington, U.K.). in a 25 µl total volume reaction in an Omni-
Gene thermal cycler (Hybaid, Teddington, U.K.). The amplification
conditions for all sets of primers were 94°C for 5 min; then 94°C for 45 s,
55°C for 45 s, 72°C for 45 s, for 40 cycles.
Conformation-sensitive gel electrophoresis analysis Mutation
detection screening was performed by heteroduplex analysis using con-
formation-sensitive gel electrophoresis (Ganguly et al, 1993). After PCR,
3–8 µl of the PCR products were heated to 98°C for 8 min, followed by
heating at 68°C for 40 min, to allow for the formation of heteroduplexes.
Also, to detect homozygous mutations, equal volumes of the probands’
PCR products were admixed with normal control PCR products before
denaturing and gel electrophoresis.
Sequencing PCR products displaying heteroduplex bandshifts were
purified using Qiaquik spin columns (Qiagen, Crawley, U.K.) and
sequenced (forward and reverse orientations) using dye terminator labeling
in an ABI 310 automated sequencer (PE; Applied Biosystems, Warrington,
U.K.). Reverse transcription–PCR products were cloned into a PCR-
compatible vector (TA; InVitrogen, Leek, the Netherlands) and
sequenced similarly.
Immunofluorescence After informed consent, skin biopsies were taken
under local anesthesia from clinically uninvolved skin (no blisters, erosions,
or scarring) from two affected individuals in each of the RDEB and JEB
families. Samples were divided for indirect immunofluorescence, electron
microscopy, and RNA extraction. Indirect immunofluorescence staining
was performed on 5 µm cryosections of skin with the monoclonal antibodies
LH7:2 (NC-1 domain of type VII collagen, a generous gift from Dr
I.M.Leigh) (Leigh et al, 1988), GB3 (conformational epitope on γ2 chain
of laminin 5, Sigma (Poole, U.K.) (Verrando et al, 1991), 233 monoclonal
antibody (extracellular portion of 180 kDa bullous pemphigoid antigen/
type XVII collagen, kindly donated by Dr K. Owaribe) (Nishizawa et al,
1993), and COL94 (type IV collagen, Sigma). The antibodies were diluted
1:2, 1:50, 1:10, and 1:100, respectively, in phosphate-buffered saline/
bovine serum albumin. For the JEB probands, additional immunofluores-
cence staining was performed using chain-specific laminin 5 antibodies,
BM165 (α3 chain) (Marinkovich et al, 1992), 6F12 (β3 chain, both
generously supplied by Dr R.E.Burgeson) (Rousselle et al, 1991), and
SE144 (γ2 chain, a gift from Dr G.Meneguzzi) (Vailly et al, 1994). All
these primary antibodies were diluted 1 : 100. Labeling procedures were
as described previously (Kennedy et al, 1985). Propidium iodide was used
as a nuclear counterstain. Fluorescein isothiocyanate-labeled anti-mouse
and anti-rabbit secondary antibodies (Dako, Glostrup, Denmark) were used
diluted 1 : 200 in phosphate-buffered saline/bovine serum albumin.
Electron microscopy Skin for electron microscopy was fixed in half-
strength Karnovsky’s fixative (containing 2.5% glutaraldehyde and 2%
paraformaldehyde) and processed using standard methods as described
previously (Eady, 1985). Ultrathin sections were stained with uranyl acetate
and lead citrate and examined in a JEOL 100CX transmission electron
microscope. In the RDEB patient skin, the number of anchoring fibrils
present beneath the lamina densa was counted using previously defined
morphometric criteria (Tidman and Eady, 1984, 1985). More than 100 µm
of continuous lamina densa was assessed and anchoring fibrils were defined
as having two or more of the following – insertion into the lamina densa,
a fan-shaped appearance, or central cross-banding. In the JEB patient
skin, a morphometric analysis of hemidesmosomes was undertaken using
standardized criteria to evaluate the number of hemidesmosomes, the
presence or absence of inner plaques, connections with the keratin filament
cytoskeleton, and the presence or absence of sub-basal dense plates over a
continuous 100 µm section of basement membrane (Tidman and Eady,
1984, 1986; McMillan et al, 1998).
RNA extraction and reverse transcriptase–PCR RNA was extracted
from 20 cryostat sections (30 µm thickness) of skin from two probands in
each family and control skin biopsies using a commercial kit (Quick Prep
Micro mRNA purification kit (Pharmacia Biotech, Little Chalfont, U.K.).
Reverse transcription was also carried out using a corresponding commercial
kit (first-strand cDNA synthesis, Pharmacia Biotech). Nested primers for
reverse transcription–PCR were designed using the Macintosh software
Oligo 4.0. Specifically, to span exon 19 of COL7A1 and neighboring
exons, the primers were as follows: outer sense primer 59-GCC-
ACAGGATACAGGGTTTC-39 (nucleotides 2134–2153 in the cDNA;
GenBank L02870), outer anti-sense primer 59-CACCACACGTAGTT-
CAATGC-39 (nucleotides 2895–2876); inner sense primer 59-CA-
GAGAAATCCCAGTTGGTT-39 (nucleotides 2174–2193), inner anti-
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Figure 1. Heterozygosity for frameshift/non-sense mutations in LAMB3 mutations is present in patients with JEB. (a) Heteroduplex analysis
of PCR products spanning exon 3 (U17745) reveals bandshifts in all samples which are similar in the paternal and control (C) DNA, but different in the
maternal DNA, which also differs from the bandshifts detected in the JEB individuals. (b) Sequencing of DNA from the mother and the two affected
individuals demonstrates a heterozygous frameshift mutation (29insC). This mutation was not present in the paternal or control DNA samples. A silent
threonine polymorphism 109 bp downstream from the site of the mutation (138 C-to-T, ACC to ACT), however, was detected in DNA from the
father, both patients, and the control DNA, but not in the mother’s DNA. These findings account for the bandshifts seen in the paternal and control
DNA and also for the differences in the type of bandshift seen in the mother and the JEB individuals. (c) Heteroduplex analysis of PCR products spanning
exon 17 of LAMB3 (U17757) reveals bandshifts in DNA from the father and two affected individuals but only homoduplex bands in the maternal and
control samples. (d) Sequencing of PCR products displaying heteroduplexes shows a heterozygous C-to-T transition at nucleotide 2500 that changes a
glutamine residue (CAG) to a non-sense codon (TAG). The mutation is designated Q834X. Sequencing of the maternal and control DNA revealed wild-
type sequence only.
sense primer 59-CAGCCCGTCCAGGTGATAGC-39 (nucleotides 2772–
2751). To span exon 3 of LAMB3 and the neighboring exons, the primer
sets were: outer sense primer 59-GCGGGAGGAGGACTGTATCT-39
(nucleotides 3–22 in the cDNA, GenBank L25541), outer anti-sense
primer 59-TGATCTCCCCCACCTCTTGA-39 (nucleotides 763–742);
inner sense primer 59-GCCTGATTTATTCCTCTTCC-39 (nucleotides
49–58 in the cDNA), inner anti-sense primer 59-CCCGAGGG-
AAGGTGGAGGTG-39 (nucleotides 598–579). To span exon 17 of
LAMB3 and the neighboring exons, the primer sets were: outer sense
primer 59-CAGAAGCTTCAATGGTCTCC-39 (nucleotides 2178–2197
in the cDNA), outer anti-sense primer 59-TTGGTCTGGATCTCATT-
CAT-39 (nucleotides 2978–2959); inner sense primer 59-ACAGCT-
CGCGCCTTTTGGAC-39 (nucleotides 2321–2340 in the cDNA), inner
anti-sense primer 59-GCTGACCTCCTGGATAGTGG-39 (nucleotides
2859–2840). The initial PCR amplification was as described by manufac-
turers of the RNA extraction kit, although the number of cycles was
restricted to 20. For the nested PCR, 1 µl of this PCR product was used
as template in a 40-cycle PCR reaction as described for the amplification of
genomic DNA above. The size of the expected nested reverse transcription–
PCR products was 598 bp, 549 bp, and 538 bp, respectively. Semi-
quantitative assessment of the reverse transcription–PCR products was
made by scanning a negative of a Polaroid image of the reverse transcription–
PCR agarose gel electrophoresis picture using an ultrascan laser densitometer
(LKB, Bromma, Sweden).
RESULTS
COL7A1 and LAMB3 mutations in genomic DNA predict
complete ablation of corresponding protein Heteroduplex
analysis using amplified DNA from the RDEB family revealed
bandshifts in the affected individuals for the PCR products spanning
exon 19 and flanking introns of COL7A1, but only in samples
admixed with control DNA indicating homozygosity for a
COL7A1 sequence variation. Direct nucleotide sequencing showed
a homozygous 1 bp insertion, 2470insG, which is predicted to lead
to a premature termination codon 178 bp downstream in exon 20.
Further details of this mutation have been published previously
(Salas-Alanis et al, 1998).
In the JEB family, heteroduplex bandshifts were seen in PCR
products spanning LAMB3 exons 3 and 17 and flanking introns
(Fig 1). Direct sequencing showed a maternally inherited hetero-
zygous frameshift mutation in exon 3, 29insC, and a paternally
inherited C-to-T transition at nucleotide position 2500 in exon 17
that converts a glutamine residue into a premature stop codon,
Q834X. A heterozygous silent threonine polymorphism in exon 3
at amino acid position 46 (ACC/ACT) was also detected in the
paternal, control, and affected individuals’ DNA. The mutation
29insC in exon 3 was verified by restriction endonuclease digestion
using AlwN1, as reported in other JEB families harboring this
mutation (Pulkkinen et al, 1995), and the exon 17 mutation was
confirmed by sequencing in the forward and reverse orientations
in all family members. The mutation Q834X has not been described
previously in other mutation studies and was not demonstrated in
sequencing of 100 control chromosomes.
Immunofluorescence of skin biopsies shows positive labeling
for mutated protein In the RDEB patients, staining with LH7:2
antibody (anti-type VII collagen) showed only a slight, occasionally
patchy, reduction in dermal–epidermal junction fluorescence intens-
ity compared with control skin sections (Fig 2). Laminin 5 and
anti-type IV collagen labeling showed no differences in labeling
compared with control skin, although both mapped to the roof of
blistered patient skin. In the JEB skin, labeling with the GB3 anti-
laminin 5 antibody was completely negative (Fig 3), as was the
immunostaining with the β3 chain antibody, 6F12. Positive but
reduced labeling at the dermal–epidermal junction for the γ2 chain
with the SE144 antibody was seen, however, and there was reduced
but positive staining for the α3 chain with antibody BM165. Anti-
type XVII, type VII, and type IV collagen labeling showed similar
bright linear dermal–epidermal junction staining to control skin.
Electron microscopy of skin biopsies reveals anchoring
fibril-like structures in RDEB and variable hemidesmosome
morphology in JEB In skin from the RDEB patients, electron
microscopy showed a sublamina densa level of blister formation in
keeping with a diagnosis of a dystrophic form of EB. Examination
of unblistered dermal–epidermal junction showed a variable number
of anchoring fibrils (Fig 4). Many of these had a wisp-like
morphology, but several clearly had a fan-shaped appearance with
insertion into the lamina densa and central cross-banding, all well-
characterized features of mature anchoring fibrils in normal control
skin. Morphometric assessment of anchoring fibrils revealed 26.2
fibrils/40 µm of lamina densa: the corresponding value in age-,
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Figure 2. Immunostaining of skin for
type VII collagen shows positive
labeling in RDEB patients. (a) In normal
skin there is bright, linear labeling along
the dermal–epidermal junction. (b) In the
RDEB patients’ skin the intensity of the
labeling is slightly reduced, but linear
fluorescent staining is present. Scale
bar: 50 µm.
Figure 3. Immunostaining of skin
shows alterations in laminin 5 labeling
in the JEB patients’ skin. (a) In normal
skin there is bright, linear labeling along
the dermal–epidermal junction with the
GB3 anti-laminin 5 antibody. (b) In the
JEB patients’ skin there is a complete
absence of laminin 5 immunoreactivity
using the GB3 antibody. (c) in the JEB
patients’ skin there is linear basement
membrane zone staining for type XVII
collagen, similar to control skin (not
shown). (d) Using the antibody 6F12
there is a complete absence of immuno-
staining for the β3 chain of laminin 5 in
JEB patients’ skin. (e) By contrast the
JEB patients’ skin shows positive, albeit
reduced, immunostaining at the dermal–
epidermal junction for the α3 chain of
laminin 5 (BM165 antibody) and (f) for
the γ2 polypeptide chain of laminin 5
(SE144 antibody). Arrows, dermal–
epidermal junction; Scale bar: 35 µm.
Figure 4. Some anchoring fibril-like
structures are present in RDEB skin.
Transmission electron microscopy of the
dermal–epidermal junction in the RDEB
patients shows several anchoring fibril-like
structures inserting into the lamina densa
(arrows). Some of these show central cross-
banding, but most are thinner and less fan-
shaped than anchoring fibrils in control
skin. Scale bar: 0.5 µm.
site-, and sex-matched control skin has previously been shown to
be 37.1 (95% confidence intervals 11.9–62.3) (Tidman and Eady,
1984). In the JEB patients, blister formation was demonstrated
within the lamina lucida and ultrastructural variability in hemides-
mosome morphology was seen. The number of hemidesmosomes
was only slightly reduced in some areas, with the hemidesmosomes
often appearing hypoplastic with impaired association with the
intermediate filament network of basal keratinocytes (Fig 5). Other
hemidesmosomes retained morphologic features of inner and outer
hemidesmosomal plaques but were still hypoplastic compared with
control skin sections from age-, sex-, and site-matched control
skin. The overall number of hemidesmosomes in patient skin was
74/40 µm of basement membrane, similar to control skin counts
of 66–75/40 µm (Tidman and Eady, 1984, 1986). A considerable
reduction in the number of hemidesmosomes with clearly definable
inner plaques was noted, however, in patient skin expressed as a
percentage of the total (60.2 vs 90.1 6 1.9 SEM in control skin)
(McMillan et al, 1998). Likewise, the number of hemidesmosomes
associating with the keratin filament network was reduced (58.4 vs
83.3 6 3.3 SEM in control skin) McMillan et al, 1998). Most
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Figure 5. Hemidesmosome morpho-
logy is variable in the JEB skin. Trans-
mission electron microscopy of the dermal–
epidermal junction in the JEB patients
shows that the hemidesmosomes (open
arrows) are variably hypoplastic with absent
or small inner plaques and inconspicuous
sub-basal dense plates. Scale bar: 0.5 µm.
Figure 6. Evidence for partial rescue
of mutant COL7A1 transcripts in
RDEB. (a) Reverse transcription–PCR
amplification of cDNA spanning exon 19
of COL7A1 and adjacent exons. In the
control sample a single band of 598 bp is
present. By contrast in the DEB indivi-
duals, two bands of 599 and 451 bp are
present. (b) Sequencing of cloned reverse
transcription–PCR product from the DEB
patients shows the presence of the mutation
2470insG in the 599 bp band. (c) Sequen-
cing of the 451 bp band reveals in-frame
skipping of exon 19. (d) The skipping of
exon 19 removes 49 amino acids from
within the seventh fibronectin III-like
domain within the NC-1 region of type
VII collagen but restores the reading frame
for the remainder of the downstream NC-
1 domain, triple helix and NC-2 domain.
notably, the number of hemidesmosomes with detectable sub-basal
dense plates was reduced in patient skin (4.4 vs 31.0 6 2.0 in
control skin) (McMillan et al, 1998).
Reverse transcription–PCR and sequencing of aberrant
splice variants in COL7A1 shows evidence of partial rescue
of mutant transcripts Agarose gel electrophoresis of the reverse
transcription–PCR product spanning COL7A1 exon 19 and
neighboring exons in control cDNA showed a single band 598 bp
in size. By contrast, in the RDEB patients, two bands of differing
sizes, 599 and 451 bp were identified (Fig 6). Sequencing of cloned
reverse transcription–PCR products showed that the 599 bp band
contained the mutation 2470insG, as delineated in the genomic
DNA. The 451 bp band represented aberrant splicing with in-
frame skipping of 147 bp containing exon 19 which results in
deletion of 49 amino acids from the NC-1 domain of type VII
collagen. Based on the relative intensities of the reverse transcrip-
tion–PCR products, the ratio of the transcript containing the
frameshift mutation to that with the in-frame skip of exon 19 was
approximately 1:1. By scanning densitometry, both of these bands
were approximately 15–20% of the intensity of the control 598 bp
reverse transcription–PCR product.
Reverse transcription–PCR and sequencing of aberrant
splice variants in LAMB3 shows evidence for partial rescue
of mutant transcripts Agarose gel electrophoresis of the nested
reverse transcription–PCR product spanning LAMB3 exon 3 and
neighboring exons in the JEB probands’ and control cDNA showed
a single band 549 bp in size. Sequencing of the cloned reverse
transcription–PCR product showed a wild-type sequence in the
control sample and 14 of 24 subcloned patient reverse transcription–
PCR products. In the remaining patient clones the mutation
29insC was delineated. This mutation leads to a premature termina-
tion codon 126 bp downstream in exon 4. No evidence for aberrant
splicing induced by this frameshift mutation was identified, even
though this mutation occurs in the first nucleotide position of
exon 3 in LAMB3. Agarose gel electrophoresis of the reverse
transcription–PCR product spanning LAMB3 exon 17 and neigh-
boring exons in control cDNA revealed a single band of 538 bp.
By contrast, amplification of the corresponding cDNA in the JEB
patients demonstrated three bands, 538, 340, and 195 bp in size
(Fig 7). Sequencing of cloned reverse transcription–PCR products
showed the presence of the Q834X mutation in the patients’
538 bp product in 12 of 12 clones, with no evidence of amplification
of wild-type sequence from the other allele. Sequencing of the
340 bp band revealed in-frame skipping of exon 17 of LAMB3.
Exon 17 contains 198 bp and skipping of the exon would be
expected to result in truncation of 66 amino acids including
the most 39 amino acid of domain II, the entire α domain and
part of domain I of the laminin 5 β3 chain polypeptide. Based on
the reverse transcription–PCR findings, the ratio of the transcript
containing the non-sense mutation to that containing the in-frame
exon skip of exon 17 was approximately 1 : 1. Using scanning
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Figure 7. Evidence for partial rescue
of mutant LAMB3 transcripts in JEB.
(a) Reverse transcription–PCR amplifica-
tion of cDNA spanning exon 17 of LAMB3
and adjacent exons. In the control sample
a single band of 538 bp is present. By
contrast in the JEB individuals, additional
bands of 340 and 195 bp are present. (b)
Sequencing of cloned reverse transcrip-
tion–PCR product from the JEB patients
shows the presence of the mutation Q834X
in the 538 bp band. (c) sequencing of the
340 bp band, of similar intensity to the
larger band, reveals in-frame skipping of
exon 17. (d) Sequencing of the faint smallest
band demonstrates out-of-frame skipping
of exon 17 and 18. (e) The skipping of
exon 17 leads to removal of 66 amino
acids, including the most 39 amino acid of
domain II, the entire α domain and part
of domain I of the β3 polypeptide chain.
The deleted region also contains six
cysteine residues which are involved in
trimeric laminin 5 assembly.
densitometry, these bands were approximately 35–40% of the
relative intensity of the control 340 bp reverse transcription–PCR
product. Sequencing of the faint 195 bp reverse transcription–PCR
product showed evidence for further aberrant splicing with skipping
of both exon 17 (198 bp) and 18 (145 bp). This splice variant
results in frameshift and a downstream premature termination
codon in exon 19 of LAMB3.
DISCUSSION
Accurate splicing of exons is dependent on several components of
genomic DNA including splice donor and acceptor sites, exon
enhancer sequences, and intronic polypyrimidine and branchpoint
regions (Berget, 1995; Adams et al, 1996). Although mutations
directly affecting these sites may result in aberrant splicing, other
types of mutations including non-sense and mis-sense mutations
may also influence splice site selection (Cooper and Mattox,
1997). Likewise, large insertions, deletions, or multiple nucleotide
substitutions can all influence exon splicing (Cooper and Mattox,
1997). Recently, in dominant DEB, internal deletions within an
exon encoding part of the type VII collagen triple helix have
been shown to result in exon skipping or aberrant splicing with
restoration of the open-reading frame (Cserhalmi-Friedman et al,
1998; Sakuntabhai et al, 1998). Dominant-negative interference
between the truncated and wild-type protein gives rise to the
dominant DEB phenotype which is indistinguishable from other
cases of dominant DEB caused by glycine substitutions in the type
VII collagen triple helix, the usual type of mutation in this subtype
of the disease. These dominant DEB internal deletions in COL7A1
are expected to alter the sequence, size, and/or secondary structure
of the exons, although the precise mechanism of action through
which aberrant splicing arises is not yet clear.
Proposed mechanisms for splice-site selection in these
COL7A1 and LAMB3 mutations Intron and exon sequencing
in our RDEB and JEB patients showed the presence of normal
consensus splice sites, indicating an alternative splicing control
mechanism or probable disruption of other regulatory regions; for
example, within the exons, to account for the alterations in splice
site selection. Skipping of exons containing non-sense mutations
has been demonstrated in several other genes (Cooper and Mattox,
1997). Although the precise basis of the exon skipping is not fully
known, the process is thought to involve a mechanism that
recognizes the non-sense codon before mRNA splicing with
scanning of the frame of the precursor mRNA by ribosome-like
molecules in the nucleus (Urlaub et al, 1989; Dietz et al, 1993;
Dietz and Kendzior, 1994). This mechanism may account for the
skipping of exon 17 of LAMB3 containing the mutation Q834X
in our JEB patients. Of interest in our RDEB patients was the
detection of mRNA transcripts showing in-frame skipping of exon
19 of COL7A1 containing the mutation 2470insG, particularly as
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the downstream premature termination codon arising from this
mutation is in exon 20. These observations suggest the presence
of a further mechanism governing the control of exon splicing.
Both the mutation 2470insG in COL7A1 and the mutation Q834X
in LAMB3 occur in purine-rich regions of their corresponding
exons. It is known that in some exons purine-rich sequences may
act as splicing enhancers by interacting with splicing factors and
cis-acting intronic elements to help define exons: these sequences
are referred to as exon splicing elements or exon recognition
sequences (Watakabe et al, 1993; Tanaka et al, 1994). The mutation
2470insG in COL7A1 occurs in the sequence AGGGAAA (muta-
tion underlined) and it is possible that this insertion disrupts an
exon recognition sequence, particularly as the introduction of
poly(G) has previously been shown to result in loss of splicing
enhancer activity (Tanaka et al, 1994). The disruption of an exon
splicing element also appears to be relevant to the mutation Q834X
in LAMB3. This mutation occurs in the sequence GGGGTAGG
and other studies have demonstrated a loss of enhancer activity
resulting from the replacement of C by T/U in such a sequence
(Tanaka et al, 1994; Santisteban et al, 1995). Variability in phenotype
may also reflect differences in the processing, regulation, and
stability of non-sense transcripts. Recently, a new gene, rent1, with
such a putative regulatory role has been described (Perlick et al,
1996), and it is possible that the alleles bearing the COL7A1/
LAMB3 frameshift/non-sense mutations also involve co-inheritance
of a non-sense transcript modifying haplotype that imparts some
stability to these particular mutations. A further possible explanation
may reflect other differences in the efficiency of the non-sense-
mediated mRNA decay pathway. Indeed, the significance of certain
sequences downstream from a non-sense mutation, which either
enhance or reduce the activity of non-sense-mediated mRNA
decay, has been documented in experimental systems (Ruiz-
Echevarria et al, 1998).
Revising the paradigms of genotype–phenotype correlations
in EB The molecular findings in our patients also have important
implications for understanding genotype–phenotype correlation in
this group of inherited skin diseases (Jarvikallio et al, 1997). In
RDEB, a number of different types of pathogenic COL7A1
mutation have been described including non-sense mutations,
frameshift mutations, ‘‘silent’’ glycine substitutions, and splice
acceptor and donor site mutations (Hovnanian et al, 1997). The
nature or combinations of these mutations helps explain some of
the variation in phenotype seen in this disorder. The findings of
relatively mild RDEB resulting from a homozygous frameshift
mutation in the NC-1 domain, as in the Mexican family studied,
however, have not been previously reported. By current paradigms,
one would have predicted the three sisters, homozygous for
2470insG in COL7A1, to have severe, generalized, mutilating
disease (Hilal et al, 1993; Christiano et al, 1995), yet this was not
the case. Indeed, we are aware of other Mexican families with the
same mutation with affected individuals now in their 70s (JCSA,
unpublished data). None of these has any severe contractures and
none has developed other complications associated with RDEB,
such as squamous cell carcinoma. In addition, several have borne
children without suffering any significant blistering or difficulties
in perineal healing related to their RDEB. Our study, therefore,
has shown the importance of characterizing the consequences of
mutations in genomic DNA at the transcriptional level to explain the
moderation of clinical severity. The COL7A1 mutation 2470insG
resulted in in-frame deletions affecting part of the nine fibronectin
III-like repeat domains within the NC-1 region of type VII collagen
(Christiano et al, 1994b). Computer modeling of these type III
fibronectin repeats predicts structure akin to suction cups and
therefore deletion of part of one of these domains would be
expected to compromise but not totally disrupt dermal–epidermal
adhesion. The in-frame deletion affecting the downstream part of
the seventh repeat domain only partially perturbs construction of
anchoring fibrils as, despite lacking part of one of these adhesive
units, many of the resulting anchoring fibrils still had central cross-
banding and a fan-shaped appearance.
The nature of the mutations in the German JEB family and their
effects on protein expression are also noteworthy. If compound
heterozygosity for 29insC and Q834X in LAMB3 had been
detected in these children as neonates, then taken with the
immunohistochemical observations of undetectable immuno-
staining with the GB3 antibody, one would have predicted a
clinical course of Herlitz disease, with demise of the affected
individuals in early childhood (Pulkkinen et al, 1994; Uitto et al,
1995). Only one similar exception to this LAMB3 genotype–
phenotype correlation has been described previously and in that
case no skin biopsy was available for further assessment (Pulkkinen
and Uitto, 1998). Immunolabeling of skin in our JEB patients
using chain-specific laminin 5 antibodies did provide some unusual
findings, specifically the absence of staining for the β3 chain and
trimeric laminin 5 and reduced but positive labeling for the α3
and γ2 chains. The lack of staining for the β3 chain may be due
to loss of epitopes caused by the mutation(s), although the precise
binding domain of the 6F12 antibody is not known. Changes in
both the quality and quantity of laminin 5, as well as the sensitivity
and specificity of the antibodies used may help explain the immuno-
fluorescence findings. Of note, the BM165 antibody is known to
have cross-reactivity with the α3 chain of laminin 6 (Burgeson
et al, 1994), and the lack of correlation between laminin 5 mutations
and chain-specific immunostaining patterns has been demonstrated
previously (McMillan et al, 1997). In these JEB patients, the
LAMB3 exon 3 mutation 29insC did not influence splice site
selection and resulted in a downstream stop codon in exon 4.
Reverse transcription–PCR analysis of the mutation Q834X in
exon 17, however, showed some transcripts with in-frame skipping
of exon 17 resulting in deletion of 66 amino acids from the laminin
5 β3 polypeptide. Unlike its neighboring exons in LAMB3, exon
17 contains several cysteine residues which may have a role in
disulfide bonding and stabilization of trimeric laminin 5 (Pulkkinen
et al, 1995). This adhesive function is severely compromised through
skipping of exon 17, although the clinical consequences are not
lethal and the phenotype is that of nonlethal generalized atrophic
benign EB, other cases of which have been shown to result from
non-sense/mis-sense combinations of mutations in LAMB3 or
non-sense mutations in the gene encoding type XVII collagen,
COL17A1 (Darling et al, 1998). Electron microscopy demonstrated
that the most profound consequence of the mutations 29insC/
Q834X was in the reduction of the number of sub-basal dense
plates, although other parameters of hemidesmosomal assembly
such as the presence of inner plaques and keratin filament association
were also compromised. The changes were not as marked, however,
as in patients with other combinations of non-sense/frameshift
mutations in laminin 5 underlying lethal forms of the disease
(McMillan et al, 1998).
In summary, accumulating mutational data on patients with
RDEB and JEB have proved useful in providing more precise
clinical information, particularly in defining diagnosis and in
improving genetic counseling. As the mutation database in these
disorders increases, however, it is becoming evident that there are
limitations in relying exclusively on the findings of mutation analysis
of genomic DNA alone to establish prognosis in an affected
individual. Rather, an accurate interpretation of the significance of
the molecular pathology should also involve immunohistochemical
and ultrastructural assessment of skin and, in some instances, analysis
of mRNA processing.
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